Ghassan Allo

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <scp>HER2</scp> targeting in 19% of carcinomas

Michael S. Anglesio, Stefan Kommoss, Mary Catherine Tolcher et al. · The Journal of Pathology · 2012 · 197 citations · Full text

Medicine, Oncology, Pathology +17

miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma

Heba Khella, Marize Bakhet, Ghassan Allo et al. · Carcinogenesis · 2013 · 166 citations · Full text

Medicine, Cancer Biology, Oncology +15

ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas

Ghassan Allo, Marcus Q. Bernardini, Ren‐Chin Wu et al. · Modern Pathology · 2013 · 133 citations · Full text

Medicine, Molecular Genetics, Oncology +15

Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i>-Mutant Lung Adenocarcinoma

Erin Stewart, Céline Mascaux, Nhu‐An Pham et al. · Journal of Clinical Oncology · 2015 · 119 citations

Medicine, Cancer Biology, Oncology +17

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Anna V. Tinker, Susan Ellard, Stephen Welch et al. · Gynecologic Oncology · 2013 · 101 citations

Medicine, Oncology, Chemotherapy +15